全文获取类型
收费全文 | 1435篇 |
免费 | 140篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 44篇 |
妇产科学 | 56篇 |
基础医学 | 288篇 |
口腔科学 | 32篇 |
临床医学 | 191篇 |
内科学 | 278篇 |
皮肤病学 | 38篇 |
神经病学 | 102篇 |
特种医学 | 24篇 |
外科学 | 154篇 |
综合类 | 8篇 |
一般理论 | 2篇 |
预防医学 | 144篇 |
眼科学 | 51篇 |
药学 | 72篇 |
肿瘤学 | 88篇 |
出版年
2024年 | 2篇 |
2023年 | 10篇 |
2022年 | 17篇 |
2021年 | 29篇 |
2020年 | 26篇 |
2019年 | 46篇 |
2018年 | 37篇 |
2017年 | 51篇 |
2016年 | 41篇 |
2015年 | 40篇 |
2014年 | 57篇 |
2013年 | 88篇 |
2012年 | 151篇 |
2011年 | 114篇 |
2010年 | 56篇 |
2009年 | 55篇 |
2008年 | 86篇 |
2007年 | 80篇 |
2006年 | 91篇 |
2005年 | 78篇 |
2004年 | 81篇 |
2003年 | 57篇 |
2002年 | 47篇 |
2001年 | 17篇 |
2000年 | 14篇 |
1999年 | 11篇 |
1998年 | 11篇 |
1997年 | 13篇 |
1996年 | 15篇 |
1995年 | 12篇 |
1994年 | 10篇 |
1993年 | 11篇 |
1992年 | 23篇 |
1991年 | 12篇 |
1990年 | 15篇 |
1989年 | 12篇 |
1988年 | 11篇 |
1987年 | 11篇 |
1986年 | 7篇 |
1985年 | 3篇 |
1984年 | 3篇 |
1983年 | 2篇 |
1982年 | 3篇 |
1981年 | 2篇 |
1977年 | 3篇 |
1975年 | 5篇 |
1973年 | 3篇 |
1972年 | 2篇 |
1971年 | 2篇 |
1966年 | 2篇 |
排序方式: 共有1579条查询结果,搜索用时 0 毫秒
31.
32.
Anneke T. Vulto-van Silfhout Conny M.A. van Ravenswaaij Jayne Y. Hehir-Kwa Eugène T.P. Verwiel Rita Dirks Steven van Vooren Albert Schinzel Bert B.A. de Vries Nicole de Leeuw 《European journal of medical genetics》2013,56(9):471-474
The European Cytogeneticists Association Register of Unbalanced Chromosome Aberrations (ECARUCA, www.ecaruca.net) is an online database initiated in 2003 that collects and provides detailed, curated clinical and molecular information on rare unbalanced chromosome aberrations. ECARUCA now contains over 4800 cases with a total of more than 6600 genetic aberrations and has over 3000 account holders worldwide. Recently, the ECARUCA web site was renewed, including the presentation of interesting case reports in collaboration with the European Journal of Medical Genetics. This article gives an overview of the current status and future plans of the online ECARUCA database. 相似文献
33.
34.
35.
Johanna Temme Anneke Kramer Kitty J. Jager Katharina Lange Frederick Peters Gerhard-Anton Müller Reinhard Kramar James G. Heaf Patrik Finne Runolfur Palsson Anna V. Reis?ter Andries J. Hoitsma Wendy Metcalfe Maurizio Postorino Oscar Zurriaga Julio P. Santos Pietro Ravani Faical Jarraya Enrico Verrina Friedo W. Dekker Oliver Gross 《Clinical journal of the American Society of Nephrology》2012,7(12):1969-1976
36.
37.
Verena Tenten Sylvia Menzel Uta Kunter Eva-Maria Sicking Claudia R. C. van Roeyen Silja K. Sanden Michaela Kaldenbach Peter Boor Astrid Fuss Sandra Uhlig Regina Lanzmich Brigith Willemsen Henry Dijkman Martin Grepl Klemens Wild Wilhelm Kriz Bart Smeets Jürgen Floege Marcus J. Moeller 《Journal of the American Society of Nephrology : JASN》2013,24(12):1966-1980
38.
Sunil W. Dutta J. Hunter Mehaffey Jason C. Sanders Max O. Meneveau Courtney Lattimore Bruce Libby David R. Brenin Anneke T. Schroen Einsley M. Janowski Carl Lynch Donna J. Lash Timothy N. Showalter Shayna L. Showalter 《Brachytherapy》2019,18(3):285-291
PurposeA multidisciplinary team at our institution developed a novel method of intraoperative breast radiation therapy (precision breast intraoperative radiation therapy [PB-IORT]) that uses high-dose-rate brachytherapy with CT on-rails imaging to deliver high-dose, customized radiotherapy to patients with early-stage breast cancer. This report summarizes our program's experience developing and implementing PB-IORT.Methods and MaterialsLiterature on PB-IORT was reviewed including published articles and abstracts. To evaluate case volume, all patients with a breast cancer diagnosis who underwent breast surgery or breast radiation (2010–2017) at our academic institution were identified. Patients were stratified into pre-IORT and post-IORT eras with initiation of our PB-IORT program in October 2013. Overall trends in surgical and radiation therapy volume in each era were analyzed by linear regression. Travel distance for all surgical patients was calculated using Google Maps (Alphabet Inc.) and then compared between IORT and non-IORT patients.ResultsData from a PB-IORT Phase 1 trial found that the primary endpoints were met and that PB-IORT is feasible and safe. The direct health system's delivery costs for PB-IORT exceed those of 16-fraction whole-breast irradiation when accounting for consumable supplies (multilumen balloon applicator = $2,750 per patient). There was a significant increase in yearly growth of breast cancer surgical volume with PB-IORT.ConclusionsAccrual rates for the ongoing Phase II trial have been quicker than expected in an area where more research is needed. The rapid accrual indicates patient interest and demand for this treatment and that it is very feasible to get more data from randomized trials. 相似文献
39.